Edition:
India

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

2,338JPY
11:30am IST
Change (% chg)

¥-18 (-0.76%)
Prev Close
¥2,356
Open
¥2,340
Day's High
¥2,344
Day's Low
¥2,318
Volume
2,122,600
Avg. Vol
1,914,332
52-wk High
¥2,670
52-wk Low
¥2,192

4568.T

Chart for 4568.T

About

DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the... (more)

Overall

Beta: 0.87
Market Cap(Mil.): ¥1,670,431.00
Shares Outstanding(Mil.): 709.01
Dividend: 35.00
Yield (%): 2.97

Financials

  4568.T Industry Sector
P/E (TTM): 30.39 30.82 32.14
EPS (TTM): 77.54 -- --
ROI: 2.97 14.45 13.99
ROE: 4.38 15.54 15.33

MEDIA-Daiichi Sankyo moves Supreme Court to block sale of promoter shares in India's Fortis Healthcare - Economic Times

- Note: Reuters has not verified this story and does not vouch for its accuracy

10 Aug 2017

BRIEF-Daiichi Sankyo and unit says settlement agreement on u.s. products liability litigation

* Says it and U.S.-based unit Daiichi Sankyo, Inc. have agreed to enter into a program to settle, on behalf of all defendants, pending product liability litigation against various Daiichi Sankyo and Forest entities

02 Aug 2017

Daiichi Sankyo settles U.S. lawsuits over blood pressure drug Benicar

NEW YORK Daiichi Sankyo on Tuesday said it has agreed to pay up to $300 million to settle some 2,300 U.S. cases accusing the Japanese drugmaker of failing to warn that its blood pressure medication Benicar can cause gastrointestinal illness.

01 Aug 2017

Daiichi Sankyo settles U.S. lawsuits over blood pressure drug Benicar

NEW YORK, Aug 1 Daiichi Sankyo on Tuesday said it has agreed to pay up to $300 million to settle some 2,300 U.S. cases accusing the Japanese drugmaker of failing to warn that its blood pressure medication Benicar can cause gastrointestinal illness.

01 Aug 2017

BRIEF-Daiichi Sankyo announces settlement on U.S. products liability litigation

* Announces settlement agreement on U.S. Products liability litigation​

01 Aug 2017

EMA panel recommends against Nektar, Daiichi Sankyo's breast cancer drug

European regulators on Friday recommended against granting approval to a breast cancer drug being developed by Nektar Therapeutics and Daiichi Sankyo's German unit.

21 Jul 2017

EMA panel recommends against Nektar, Daiichi Sankyo's breast cancer drug

July 21 European regulators on Friday recommended against granting approval to a breast cancer drug being developed by Nektar Therapeutics and Daiichi Sankyo's German unit.

21 Jul 2017

BRIEF-Daiichi Sankyo announces top-line results from phase 3 global clinical development program evaluating mirogabalin in pain syndromes

* Daiichi Sankyo announces top-line results from phase 3 global clinical development program evaluating mirogabalin in pain syndromes

30 Jun 2017

BRIEF-Daiichi Sankyo to invest 22 bln yen in U.S. for Luitpold Pharmaceuticals - Nikkei

* Daiichi Sankyo to invest 22 billion yen in U.S. for Luitpold Pharmaceuticals; targets about 70 pct rise in Luitpold's sales to 150 billion yen in fiscal 2020 versus 2015 - Nikkei Source (http://s.nikkei.com/2qhFwVe) Further company coverage:

25 May 2017

BRIEF-Daiichi Sankyo makes 15 bln yen investment

* Daiichi Sankyo - making initial 15 billion yen investment to optimize and enhance manufacturing capabilities to support growing antibody drug conjugate pipeline Source text for Eikon: Further company coverage:

27 Apr 2017

Earnings vs. Estimates